Zyprexa

The analyst consensus estimate for the year is $2.85 per share in earnings on total revenue of $14.65 billion.

Citigroup's George Grofik expects fourth-quarter earnings per share of 78 cents, and worldwide QUARTER DEVELOPMENTS: In October, Lilly and Johnson & Johnson biotech unit Centocor Inc.

permanently suspended enrollment for a clinical trial studying the blood thinner ReoPro to treat acute strokes, citing safety concerns.

In December, Lilly said it plans to file with the Food and Drug Administration to have its antidepressant Cymbalta approved for the treatment of generalized anxiety disorder.

The company also said last month it would plead guilty to a misdemeanor and pay $36 million to settle charges of off-label promotion of its Evista osteoporosis treatment in 1998.

COMPETITORS: Drug maker Pfizer Inc.

said Thursday its fourth-quarter profit fell about 3 percent to $2.73 billion, or 37 cents pe...

Read more...